

23<sup>rd</sup> August, 2023

~~The Dy. General Manager (Listing Dept.)~~

~~BSE Limited,~~

~~Corporate Relationship Dept.,  
1<sup>st</sup> Floor, New Trading Ring,  
P. J. Towers, Dalal Street, Fort,  
Mumbai - 400 001~~

~~(BSE Scrip Code: 500420)~~

~~The Manager – Listing Dept.~~

~~National Stock Exchange of India Ltd.,~~

~~Exchange Plaza, 5<sup>th</sup> Floor,  
Plot No. C/1, G. Block,  
Bandra - Kurla Complex, Bandra (E),  
Mumbai – 400 051~~

~~(NSE Scrip Code: TORNTPHARM)~~

Dear Sir,

**Sub.: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

We refer to our earlier letter dated 25-May-23 on the inspection conducted by USFDA for our Manufacturing facility at Dahej, Gujarat from 17-May-23 to 25-May-23.

In furtherance to the aforementioned intimation, this is to inform you that the USFDA has issued an Establishment Inspection Report (“EIR”) for the said manufacturing facility and the inspection has now been successfully closed by the USFDA.

Please take the information on your records.

Thanking you,

Yours faithfully,

For TORRENT PHARMACEUTICALS LIMITED

CHINTAN  
MAHESHKU  
MAR TRIVEDI

Digitally signed by  
CHINTAN  
MAHESHKUMAR  
TRIVEDI  
Date: 2023.08.23  
23:54:56 +05'30'

CHINTAN M. TRIVEDI  
COMPANY SECRETARY

**TORRENT PHARMACEUTICALS LIMITED**

CIN: L24230GJ1972PLC002126

Reg. Office : Torrent House, Off Ashram Road, Ahmedabad- 380 009, India. Phone: +91 79 26599000, Fax: +91 79 26582100

www.torrentpharma.com, Email : InvestorServices@TorrentPharma.com